Narrow search
Showing 1 - 10 of 138
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - 2010
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10014191301
Cover Image
Auditing the Prescription Drug Consumer Price Index in a Changing Marketplace
Frank, Richard G.; Hicks, Andrew; Berndt, Ernst R. - National Bureau of Economic Research - 2022
prescription pharmaceuticals dispensed in hospitals, physician/clinic outpatient facilities, and nursing homes. Thus the CPI …-Rx overlooks the increasingly important specialty pharmaceuticals dispensed in hospitals, outpatient clinics, and physician offices … drug growth differs from that of traditional pharmaceuticals, the CPI-Rx could provide an inaccurate measure of overall …
Persistent link: https://www.econbiz.de/10013388804
Cover Image
Costs, institutional mobility barriers, and market structure : advertising agencies as multiproduct firms
Silk, Alvin J. - 1994
Persistent link: https://www.econbiz.de/10000904632
Cover Image
Costs, Institutional Mobility Barriers, and Market Structure : Advertising Agencies as Multiproduct Firms
Silk, Alvin J. - 1994
advertising agency industry? This question is addressed by treating an advertising agency as a multiproduct firm. The firm … advertising messages which it creates on behalf of its clients. Evidence is presented indicating that the structure of demand and … costs in the advertising agency industry conforms to the conditions that MacDonald and Slivinski (1987) showed were required …
Persistent link: https://www.econbiz.de/10012474089
Cover Image
Costs, Institutional Mobility Barriers, and Market Structure : Advertising Agencies as Multiproduct Firms
Silk, Alvin J.; Berndt, Ernst R. - 2021
advertising agency industry? This question is addressed by treating an advertising agency as a multiproduct firm. The firm … advertising messages which it creates on behalf of its clients. Evidence is presented indicating that the structure of demand and … costs in the advertising agency industry conforms to the conditions that MacDonald and Slivinski (1987) showed were required …
Persistent link: https://www.econbiz.de/10013213074
Cover Image
The Globalization of Clinical Trials for New Medicines : Where are the Trials Going and Why?
Berndt, Ernst R.; Cockburn, Iain M.; Thiers, Fabio A. - 2014
protection, size of potential host country market for pharmaceuticals, and measures of e-readiness. We find that factors …
Persistent link: https://www.econbiz.de/10014049979
Cover Image
Pricing in the Market for Anticancer Drugs
Howard, David H.; Bach, Peter B.; Berndt, Ernst R.; … - In: Journal of Economic Perspectives 29 (2015) 1, pp. 139-62
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the...
Persistent link: https://www.econbiz.de/10011156823
Cover Image
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2011
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10009325511
Cover Image
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
Berndt, Ernst R.; Aitken, Murray L. - National Bureau of Economic Research (NBER) - 2010
The landmark Waxman-Hatch Act of 1984 represented a "grand compromise" legislation that sought to balance incentives for innovation by establishing finite periods of market exclusivity yet simultaneously providing access to lower cost generics expeditiously following patent expiration. Here we...
Persistent link: https://www.econbiz.de/10008682661
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - Kennedy School of Government, Harvard University - 2010
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10010627802